Software & SaaS

Plume Network launches institutional-grade asset vaults on Solana, connecting giants like WisdomTree to high-speed DeFi and forging a new era of real-world yield.

Beyond the GRAMMYs: How the Lipman brothers leveraged data and strategy to dominate the music industry and redefine the modern record label.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

Seegene expands to France's lucrative diagnostics market, but the real story is its plan to build an automated, data-driven health intelligence network.

Steward Partners' Florida expansion and CEO relocation highlight a new playbook for growth, focusing on community investment and employee ownership.

A new alliance aims to streamline at-home diagnostics for pharma, but who is accountable for patient data and safety in this rapidly growing market?

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A routine filing from a quant fund reveals subtle shifts in the high-stakes merger of American Axle and Dowlais. What does it mean for the bottom line?

A new partnership makes launching Global Capability Centers in India faster and more affordable, democratizing access to global talent and innovation.

KB Home's new Port Orchard community isn't just about houses; it's a new model for building that merges personalization, deep energy savings, and market strategy.

Canadian startup Tracktile secures funding to democratize AI, offering small food manufacturers the predictive operational tools once reserved for giants.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

A Japanese genomics leader is using AI and a massive local database to offer personalized cancer risk predictions, a move that could redefine preventative care.

A new report reveals billions in ad spend are vanishing into anonymously-run websites designed for ads, not people. Here's what it means for your business.

Parsons Corporation has secured a key position on a $3.5 billion DTRA contract, reaffirming its critical role in global efforts to counter weapons of mass destruction.

A shareholder lawsuit challenges Comerica's $10.9B sale to Fifth Third, citing a rushed process, CEO self-interest, and an undervalued price.